A Phase II Study Of Peg-Intron, GM-CSF And Thalidomide In Metastatic Renal Cell Carcinoma
- Determine the response to PEG-interferon alfa-2b, sargramostim (GM-CSF), and
thalidomide in patients with metastatic renal cell carcinoma.
- Determine duration of response in patients treated with this regimen.
- Determine the tolerance to and toxicity of this regimen in these patients.
- Determine the median and progression-free survival of patients treated with this
OUTLINE: Patients receive PEG-interferon alfa-2b subcutaneously (SC) on days 1 and 8,
sargramostim (GM-CSF) SC on days 1-10, and oral thalidomide once daily on days 1-21. Courses
repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then
PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Uzair B. Chaudhary, MD
Medical University of South Carolina
United States: Federal Government
|Hollings Cancer Center at Medical University of South Carolina||Charleston, South Carolina 29425|